<span item_type="fundamental" item_id="05f51ca1b95eea68cb64d89cf0f9b2be" counter_id="ST/US/CLNNW" env="prod"></span><span item_type="announcement" item_id="582313134099796993" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 15 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.85.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -5.039 M.</p><p></p><h3>Cash Flow</h3><ul><li>Cash and cash equivalents totaled $7.9 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024. Clene expects its cash and cash equivalents, together with $1.2 million raised subsequent to September 30, 2025, will be sufficient to fund operations into the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024. The decrease was primarily due to cost-saving initiatives and reduced manufacturing expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li><li>General and administrative expenses were $2.2 million for the quarter ended September 30, 2025, compared to $3.4 million for the same period in 2024, mainly due to decreases in legal fees, public and investor relations expenses, and personnel expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter ended September 30, 2025, compared to a net loss of $8.0 million, or $1.22 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li></ul><h3>Other Expenses</h3><ul><li>Total other expense was $3.1 million for the quarter ended September 30, 2025, compared to $0.2 million for the same period in 2024. The increase was primarily related to losses from changes in fair value of common stock warrant liabilities and derivative liabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Clene plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathway and expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034621/ex_855915.htm"></span></li></ul>

CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 15 K